Is a β‑human chorionic gonadotropin (β‑hCG) pregnancy test required before administering contrast to a woman of childbearing age with unknown pregnancy status?

β-hCG Testing Before Contrast Administration

A β-hCG pregnancy test should be obtained before administering contrast to women of childbearing age with unknown pregnancy status when the imaging result could alter management decisions or when pregnancy status would change the imaging approach.

Clinical Decision Framework

The decision to obtain β-hCG testing before contrast administration depends on the clinical scenario and type of contrast:

For Iodinated CT Contrast

β-hCG testing is recommended but not absolute before CT with iodinated contrast in women of childbearing age. The 2024 ACR guidelines indicate that while previously thought to require avoidance, there is no definitive evidence that iodinated contrast harms the developing embryo 1. However, knowing pregnancy status remains clinically important because:

• It influences the risk-benefit discussion with the patient
• It may change the imaging modality choice (ultrasound or MRI without contrast may be preferred)
• It affects radiation exposure considerations
• The decision to use iodinated contrast should involve balanced discussion between patient, referring clinicians, and radiology team 1

The ACR guidelines demonstrate that CT with IV contrast is performed in pregnant patients when clinically necessary, particularly for non-gynecological emergencies. In one retrospective study, CT identified pathology explaining abdominal pain in 36% of 80 pregnant patients, with 30% of those having normal ultrasound findings 2.

For Gadolinium-Based MRI Contrast

β-hCG testing is more critical before gadolinium administration because gadolinium has known potential teratogenic effects 1. The 2024 ACR guidelines state that gadolinium-based contrast is not recommended during pregnancy due to these concerns 1.

If gadolinium is deemed essential, it should only be administered when:

• The information cannot be acquired using other modalities
• It is needed to potentially affect care of the patient or fetus during pregnancy
• The ordering physician believes it is not prudent to wait until the patient is no longer pregnant
• Informed consent is obtained after discussion with the referring physician 2

Practical Algorithm

1. Obtain menstrual history and assess pregnancy possibility

   • Last menstrual period timing
   • Sexual activity history
   • Contraception use

2. If pregnancy cannot be excluded clinically:

   • Order β-hCG (serum preferred over urine for quantification)
   • Use cut-off of >5 mIU/mL for standard interpretation 3

3. If β-hCG is positive:

   • For iodinated contrast: Proceed if clinically necessary with documented discussion
   • For gadolinium: Avoid unless absolutely essential with documented rationale and consent

4. If β-hCG is negative:

   • Proceed with contrast as clinically indicated

Important Caveats

False-positive considerations: Elevated hCG can occur without pregnancy in rare cases including:

• Ovarian or pituitary tumors
• Intracranial germ cell tumors 4
• Heterophilic antibodies 5, 6
• Chronic kidney disease (14.5% of non-pregnant dialysis patients have hCG >5 mIU/mL) 3

False-negative considerations: Very early pregnancy may not yet show detectable hCG, though hCG is nearly always detectable within 16 days after ovulation 5.

The 2026 ACOG Clinical Consensus emphasizes systematic evaluation of positive hCG results to avoid misdiagnosis, particularly before invasive interventions 7.

Bottom Line

Obtain β-hCG testing before contrast administration in women of childbearing age with unknown pregnancy status. While iodinated contrast can be administered in pregnancy when clinically necessary, knowing pregnancy status allows for appropriate informed consent and consideration of alternative imaging. Gadolinium should be avoided in pregnancy unless absolutely essential, making β-hCG testing even more critical before MRI with contrast.